MedPage Today news story
The Phase III BEAT TB trial showed that a shorter, 6-month, all-oral treatment regimen (consisting of bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine or both) demonstrated noninferiority to the longer 9-month standard-of-care regimen for patients with pulmonary rifampicin-resistant TB.
The study confirmed that this new, simplified regimen can be safely utilized across entire households, including children and pregnant or breastfeeding women, expanding vital treatment options for these vulnerable populations.
Read the full news story here.
SEE ALSO:
- University of the Witwatersrand: South Africa’s TB research changes global medical practice
- GroundUp: Important advance in TB treatment
- The Clinical Trial Vanguard: The 6-month RR-TB trial the FDA should be studying as a pragmatic design blueprint
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #19, 30 June 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : MedPage Today
Related HIV and Co-Infections News
-
Liverpool School of Tropical Medicine: One person a week dies with undiagnosed and untreated TB in England, study finds
-
Think Global Health: Securing sustainable funding for civil society organizations
-
Global Fund: New rapid TB testing to reach 13 countries, bringing lifesaving diagnosis closer to communities
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.